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Summary
Background In the UK, chemotherapy is the standard treatment for inoperable, locally advanced, non-metastatic 
pancreatic cancer. Chemoradiotherapy is also an acceptable treatment option, for which gemcitabine, ﬂ uorouracil, or 
capecitabine can be used as concurrent chemotherapy agents. We aimed to assess the activity, safety, and feasibility of 
both gemcitabine-based and capecitabine-based chemoradiotherapy after induction chemotherapy for patients with 
locally advanced pancreatic cancer.
Methods In this open-label, randomised, two-arm, phase 2 trial, patients aged 18 years or older with histologically 
proven, locally advanced pancreatic cancer (with a tumour diameter of 7 cm or less) were recruited from 28 UK 
centres between Dec 24, 2009 and Oct 25, 2011. After 12 weeks of induction gemcitabine and capecitabine 
chemotherapy (three cycles of gemcitabine [1000 mg/m² on days 1, 8, 15 of a 28-day cycle] and capecitabine [830 mg/m² 
twice daily on days 1–21 of a 28-day cycle]), patients with stable or responding disease, tumour diameter of 6 cm or 
less, and WHO performance status 0–1 were randomly assigned to receive a further cycle of gemcitabine and 
capecitabine chemotherapy followed by either gemcitabine (300 mg/m² once per week) or capecitabine (830 mg/m² 
twice daily, Monday to Friday only), both in combination with radiation (50·4 Gy in 28 fractions). Randomisation (1:1) 
was done via a central computerised system and used stratiﬁ ed minimisation. The primary endpoint was 9-month 
progression-free survival, analysed by intention to treat including only those patients with valid CT assessments. This 
trial is registered with ISRCTN, number 96169987.
Findings 114 patients were registered and 74 were randomly allocated (38 to the gemcitabine group and 36 to the 
capecitabine group). After 9 months, 22 of 35 assessable patients (62·9%, 80% CI 50·6–73·9) in the capecitabine 
group and 18 of 35 assessable patients (51·4%, 39·4–63·4) in the gemcitabine group had not progressed. Median 
overall survival was 15·2 months (95% CI 13·9–19·2) in the capecitabine group and 13·4 months (95% CI 11·0–15·7) 
in the gemcitabine group (adjusted hazard ratio [HR] 0·39, 95% CI 0·18–0·81; p=0·012). 12-month overall survival was 
79·2% (95% CI 61·1–89·5) in the capecitabine group and 64·2 (95% CI 46·4–77·5) in the gemcitabine group. Median 
progression-free survival was 12·0 months (95% CI 10·2–14·6) in the capecitabine group and 10·4 months (95% CI 
8·9–12·5) in the gemcitabine group (adjusted HR 0·60, 95% CI 0·32–1·12; p=0·11). Eight patients in the capecitabine 
group had an objective response at 26 weeks, as did seven in the gemcitabine group. More patients in the gemcitabine 
group than in the capecitabine group had grade 3–4 haematological toxic eﬀ ects (seven [18%] vs none, p=0·008) and 
non-haematological toxic eﬀ ects (ten [26%] vs four [12%], p=0·12) during chemoradiation treatment; the most frequent 
events were leucopenia, neutropenia, and fatigue. Two patients in the capecitabine group progressed during the fourth 
cycle of induction chemotherapy. Of the 34 patients in the capecitabine group who received chemoradiotherapy, 
25 (74%) received the full protocol dose of radiotherapy, compared with 26 (68%) of 38 patients in the gemcitabine 
group. Quality-of-life scores were not signiﬁ cantly diﬀ erent between the treatment groups.
Interpretation Our results suggest that a capecitabine-based regimen might be preferable to a gemcitabine-based 
regimen in the context of consolidation chemoradiotherapy after a course of induction chemotherapy for locally 
advanced pancreatic cancer. However, these ﬁ ndings should be interpreted with caution because the diﬀ erence in the 
primary endpoint was non-signiﬁ cant and the number of patients in the trial was small.
Funding Cancer Research UK.
Introduction
In 2010, 8463 new cases of pancreatic cancer were 
diagnosed in the UK and 7901 people died of the disease.1 
At diagnosis, 30% of patients have locally advanced, 
inoperable disease.2 For these patients, chemotherapy 
alone or chemoradiotherapy are re garded as acceptable 
treatment options.3–6 Randomised trials7,8 that compared 
the two strategies have had conﬂ icting results and 
therefore have not been able to deﬁ ne a preferred 
standard of care.
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Investigators of several studies have proposed the use 
of induction chemotherapy to select appropriate patients 
who are most likely to beneﬁ t from chemoradiation 
treatment.9–11 This approach spares intensive local 
treatment for patients with chemotherapy-resistant or 
rapidly progressing systemic disease. Non-randomised 
studies that used this method of patient selection have 
reported overall survival of about 15–19 months.9,12–17 
The international, randomised, phase 3 study LAP-07 
(NCT00634725), which is comparing chemoradiotherapy 
with chemotherapy, is expected to be reported in 2013.
Both ﬂ uoropyrimidines and gemcitabine have been 
used concurrently with radiotherapy in patients with 
pancreatic cancer. Fluorouracil is most widely used, but 
gemcitabine radiosensitisation has been used in some 
studies because of its systemic activity in pancreatic 
cancer and potent radiosensitising properties.3,18 Three 
randomised, con trolled trials19–21 with small numbers of 
patients have compared ﬂ uorouracil with gemcitabine 
chemoradio therapy as primary treatment for locally 
advanced pan creatic cancer; one19 showed a signiﬁ cant 
overall survival beneﬁ t for gemcitabine-based treatment, 
but the others20,21 did not show a signiﬁ cant diﬀ erence 
between the regimens. A meta-analysis of these data 
again suggested a survival advantage of gemcitabine 
compared with ﬂ uorouracil chemoradiotherapy, but at 
the cost of greater toxicity.22 These data are, however, not 
conclusive enough to deﬁ ne practice, because the trials 
had small numbers of patients (19–62 per trial). No study 
has compared the activity of gemcitabine-based 
chemoradiotherapy with a chemoradiotherapy regimen 
that uses the oral ﬂ uoro uracil prodrug capecitabine for 
treatment of locally advanced pancreatic cancer.
We designed the SCALOP (Selective Chemoradiation 
in Advanced LOcalised Pancreatic Cancer) trial to assess 
the activity, safety, and feasibility of induction chemo-
therapy followed by chemoradiotherapy and to identify 
the relative beneﬁ ts and toxicities of gemcitabine and 
capecitabine as concurrent chemotherapy agents.
Methods
Study design and patients
The SCALOP trial was a multicentre, open-label, 
randomised, parallel, two-arm, phase 2 trial. Patients 
aged 18 years or older were eligible if they had histo-
logically or cytologically proven, locally advanced, non-
metastatic, and inoperable (or operable but medically 
unﬁ t for surgery) pancreatic cancer; a tumour diameter 
of 7 cm or less; WHO performance status 0–2; and 
adequate haematological, liver, and renal function (full 
inclusion and exclusion criteria are listed in the 
appendix). All potential patients were discussed at 
regional pancreatic multidisciplinary team meetings in 
the presence of specialist pancreatic surgeons and 
radiologists for decisions about inoperability, but the 
exact criteria for inoperability were left to the treating 
multidisciplinary team. Decisions with respect to 
patients deemed medically unﬁ t for surgery were taken 
by the treating clinicians, on the basis of the patient’s 
comorbidities and the team’s opinion about whether or 
not they could withstand major pancreatic surgery.
Response after three cycles of induction gemcitabine 
and capecitabine chemotherapy was assessed with a CT 
scan. Patients were eligible for random allocation if they 
had responding or stable disease (according to RECIST 
criteria, version 1.1); a tumour diameter of 6 cm or less; 
WHO performance status 0–1; adequate haematological, 
liver, and renal function (as for registration); and no 
greater than 10% weight loss from baseline (deﬁ ned as 
weight at registration).
All patients had to provide written informed consent 
before registration and the trial protocol was approved by 
the UK Medicines and Healthcare Products Regulatory 
Agency and a multicentre research ethics committee. 
The SCALOP trial was sponsored by Cardiﬀ  University 
and coordinated by the Wales Cancer Trials Unit (WCTU) 
at Cardiﬀ  University. The study protocol is available from 
the WCTU website.
Randomisation and masking
After three cycles of induction chemotherapy, eligible 
patients were randomly assigned in a 1:1 ratio to receive 
either gemcitabine-based or capecitabine-based chemo-
radiotherapy, by use of the method of minimisation with 
a random element (80:20). Randomisation was stratiﬁ ed 
by recruiting hospital, WHO performance status (0 vs 1), 
and disease location (head vs body or tail). The research 
nurses who recruited the patients telephoned the WCTU, 
where randomisation was done on a com puterised 
system by a trial or data manager. The study had an open-
label design, so treatment allocation was not masked 
from patients or investigators.
Procedures
Induction chemotherapy consisted of three cycles of 
gemcitabine (1000 mg/m² intravenously for 1 h on days 
1, 8, and 15 of a 28 day cycle) and capecitabine (830 mg/m² 
orally, twice daily on days 1–21 of a 28 day cycle). Patients 
eligible for randomisation were allocated to receive a 
further cycle of gemcitabine and capecitabine chemo-
therapy at the same doses as were used during induction, 
followed by radiotherapy in combination with either 
gemcitabine (300 mg/m² once per week, total six doses) 
or capecitabine (830 mg/m² twice daily on days of 
radiotherapy [Monday to Friday only]) A total dose of 
50·4 Gy in 28 daily fractions (Monday to Friday only) was 
delivered over 5·5 weeks by use of 3D conformal or 
intensity-modulated radiotherapy planning.
Dose modiﬁ cations for gemcitabine were made on the 
basis of neutrophil and platelet counts on the day of 
(or day before) administration, as previously described.23 
Capecitabine was withheld for grade 2 or higher 
non-haematological toxic eﬀ ects until they resolved to 
grade 1; for recurrent grade 2 toxic eﬀ ects, doses were 
See Online for appendix
For the study protocol see 
http://www.wctu.org.uk/trial.
php?trial=scalop
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sequentially reduced to 75% and then 50%. Dose 
reductions made during induction chemotherapy were 
maintained during the chemoradiotherapy phase. 
Chemo radiotherapy was dis continued if grade 3 or 
higher gastrointestinal toxic eﬀ ects recurred more than 
once during chemoradiation treatment. Permitted dose 
reductions were predeﬁ ned in the study protocol.
All patients underwent contrast-enhanced planning CT 
simulation with 200–300 mL water as oral contrast. 
Gross tumour volume consisted of the primary tumour 
and any node with short axis diameter of 1 cm or more. 
Planning target volume included the gross tumour 
volume with a margin of 2·0 cm in the craniocaudal 
direction and 1·5 cm in all other directions. Prophylactic 
irradiation of uninvolved regional nodes was not done. 
The mandated Radiotherapy Trials Quality Assurance 
(RTTQA) programme consisted of a detailed radiotherapy 
protocol developed by the trial management group and 
the Cardiﬀ  NCRI RTTQA Centre; a radiotherapy atlas 
that consisted of two cases (one pancreatic head tumour 
and one pancreatic body tumour) with the gross tumour 
volume outlined as per the RTTQA radiotherapy protocol; 
and a pretrial test case (inoperable carcinoma, head of 
pancreas). Gross tumour volume had to be outlined by 
the lead investigator and gastrointestinal radiologist 
from each centre and radiotherapy planned as per the 
trial protocol. The tumour outlines and the radiotherapy 
plans were assessed centrally and fed back to 
investigators. On-trial RTTQA consisted of a planning 
assessment form, which was completed during planning 
for each patient and reviewed centrally before the start of 
radiotherapy.
Assessments in the treatment period and during 
follow-up consisted of medical history, physical exam-
ination, and assessment of WHO performance status 
and toxic eﬀ ects. Capecitabine compliance was assessed 
by counting the number of tablets at each visit. Labora-
tory tests included haematological and biochemical tests, 
including tumour marker (CA19-9) assessments at 
stipulated timepoints (at registration and at 17, 26, 39, 
and 52 weeks). Contrast-enhanced CT scans of thorax 
and abdomen to assess response were done at baseline 
(registration), at 13 weeks (before randomisation), and at 
weeks 26, 39, and 52. RECIST (version 1.1) criteria were 
used for response reporting. Patients were clinically 
reviewed (including full blood counts and serum renal 
and liver proﬁ les) every 4 weeks during induction 
chemotherapy, every week during chemoradiotherapy, 
and every 12 weeks thereafter, until the ﬁ nal follow-up 
visit at week 52. At each visit, toxic eﬀ ects were reported 
as per Common Terminology Criteria of Adverse Events 
(CTCAE, version 3.0). After chemoradiotherapy, all 
patients were dis cussed by the regional multidisciplinary 
team and were reassessed for operability, with suitable 
patients taken to surgery. Those not suitable for surgery 
were kept on trial follow-up and additional chemotherapy 
was not recom mended unless disease progression was 
seen. Progres sion was deﬁ ned according to radiological 
criteria, and an isolated rise in CA19-9 was not regarded 
as a criterion for progression. Treatment after progression 
was as per institutional practice, and no speciﬁ c regimen 
was recommended.
Subsequent management beyond the trial follow-up 
period was at the discretion of the treating physician, but 
outcome data (death and disease progression) were 
collected every 3 months for those patients who had 
completed the 52-week assessment until the last patient 
had completed this assessment. Quality-of-life 
questionnaires (EORTC QLQ-C3024 and PAN26) were 
done at registration, week 17 (after induction chemo-
therapy), week 23 (immediately after chemo radiotherapy), 
and at weeks 26, 39, and 52. PAN26 results are not 
reported here; a detailed quality-of-life anaysis is planned, 
which will include these results.
Statistical analysis
The primary endpoint of the trial was progression-free 
survival at 9 months. Progression-free survival was chosen 
in preference to overall survival because, on the basis of 
the study by Huguet and colleagues,9 we anticipated that 
activity could be detected earlier and with fewer patients.
A Fleming’s single-stage design was assigned to each of 
the treatment groups to show worthwhile eﬃ  cacy in each 
group separately—ie, the study was not formally powered 
to compare 9-month progression-free survival between 
the groups. We judged that progression-free survival at 
9 months after registration of less than 30% would not be 
suﬃ  ciently large to warrant further investigation in a 
phase 3 setting, but that 50% or higher would warrant 
further investigation. Using Fleming’s single-stage 
36 allocated to capecitabine group 38 allocated to gemcitabine group
216 assessed for eligibility
102 excluded
         79 did not meet inclusion criteria
         19 declined to participate
           4 other reasons
114 registered
40 excluded
      15 progressed
      10 excluded by clinician (because of intolerance, 
            surgery needed for complications, or weight 
            loss)
        9 opted out 
        5 died
        1 should not have been registered
74 randomly allocated
Figure 1: Trial proﬁ le
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design (p1=0·30 and p2=0·50, setting α=0·1 [1-sided], 
90% power), 38 participants needed to be allocated to 
each arm. We estimated that 25% of participants would 
either withdraw or not be eligible for random allocation at 
13 weeks after registration, and that a minimum of 
102 participants would therefore need to be recruited. 
Secondary endpoints were median and 12-month overall 
survival, median (including local and distant) progression-
free survival, toxic eﬀ ects (as per CTCAE, version 3.0), 
objective disease response, treatment compliance, and 
quality of life.
Analysis was done with the Stata 11 statistical package. 
The Clopper-Pearson exact binomial method was used 
to calculate 80% CIs for the primary endpoint of 
9-month progression-free survival. Survival times were 
calculated from date of registration to that when an 
event occurred (ie, progression according to RECIST 
criteria or any death for progression-free survival, and 
any death for overall survival). Event-free patients were 
censored at the time last seen. Event time distributions 
were estimated by the Kaplan–Meier method and 
compared by use of an unadjusted log-rank test and 
hazard ratios (HRs) from Cox regression, both 
unadjusted and adjusted for randomisation stratiﬁ cation 
factors (the proportional hazards assumption was tested 
by use of Cox-Snell residuals and Schoenfeld’s global 
test). Local progression-free survival was deﬁ ned as 
time to progression without metastases or death by any 
cause. Distant progression-free survival was deﬁ ned as 
time to progression with metastases or death by any 
cause. Eﬃ  cacy endpoints were analysed according to 
the intention-to-treat principle—ie, all randomised 
patients who met the eligibility criteria were included in 
the analysis of their allocated group—whereas the 
analysis of toxic eﬀ ects was restricted to patients who 
received at least 1 week of treatment. Objective disease 
response and 9-month progression-free survival were 
only assessed in those patients with valid CT 
assessments, deﬁ ned as having been done within 
4 weeks of the timepoints stipulated in the protocol 
(weeks 26, 39, and 52). Toxicity was assessed by 
comparing pro portions of haematological and non-
haematological toxic eﬀ ects during chemoradiotherapy 
between treatment groups with Pearson’s χ² tests. 
Quality-of-life scores and CA19-9 concentrations were 
not normally distributed so were compared with 
Wilcoxon rank-sum tests. All analyses were prespeciﬁ ed 
in a statistical analysis plan.
This trial is registered at ISRCTN, number 96169987.
Capecitabine 
group (n=34)*
Gemcitabine 
group (n=38)
Chemotherapy
No dose reductions 23 (68%) 19 (50%)
Completed at least four weeks of 
chemotherapy at 100% dose
26 (76%) 30 (79%)
Stopped chemotherapy before 
6 weeks
4 (12%) 10 (26%)
Reasons for stopping
Haematological eﬀ ects 0 5 (13%)
Fatigue 0 2 (5%)
Liver function 2 (6%) 0
Diarrhoea 1 (3%) 0
Hand-foot syndrome 1 (3%) 1 (3%)
Sepsis 0 1 (3%)
Patient request 0 1 (3%)
Radiotherapy
Full protocol dose 25 (74%) 26 (68%)
25–27 fractions given 7 (21%) 8 (21%)
20–24 fractions given 0 3 (8%)
1–19 fractions given 2 (6%) 1 (3%)
No radiotherapy given 2 (6%) 0
Median dose Gy (IQR) 50·4 (48·6–50·4) 50·4 (48·6–50·4)
Data are n (%), unless otherwise stated. *Two patients in the capecitabine group 
are excluded because they progressed during the fourth cycle of induction 
chemotherapy before any chemoradiation treatment could be given.
Table 2: Treatment compliance during chemoradiotherapy
Capecitabine 
group (n=36)
Gemcitabine 
group (n=38)
Patients 
excluded at 
randomisation 
(n=40)
At enrolment (week 0)
Age (years) 63·1 (56·5–70·2) 66·0 (57·7–70·3) 64·2 (59·4–70·0)
Sex
Male 17 (47%) 24 (63%) 22 (55%)
Female 19 (53%) 14 (37%) 18 (45%)
WHO performance status
0 20 (56%) 20 (53%) 15 (38%)
1 14 (39%) 17 (45%) 20 (50%)
2 2 (6%) 1 (3%) 5 (13%)
Mean estimated longest diameter of primary 
lesion (SD), cm
4·0 (1·2) 4·0 (1·5) 4·5 (1·6)
Missing data 0 2 (5%) 1 (3%)
Number of days from staging CT scan to 
registration
7·0 (5·0–15·0) 5·0 (2·0–9·0) 10·0 (5·0–17·0)
Number of days from registration to start of 
chemotherapy
3·0 (1·0–5·0) 1·5 (0–4·0) 3·0 (1·0–6·0)
CA19-9 concentration (U/mL) 160 (27–710) 237 (110–971) 623 (95–1885)
Missing data 4 (11%) 3 (8%) 1 (3%)
At randomisation (week 13)
WHO performance status
0 15 (42%) 16 (42%) ··
1 21 (58%) 22 (58%) ··
Site of pancreatic tumour
Head 31 (86%) 32 (84%) ··
Body or tail 5 (14%) 6 (16%) ··
Number of days from registration to start of 
chemoradiotherapy
118·5 (115–125) 118·5 (116–123) ··
Progressed before start of chemoradiotherapy 2 (6%) 0 ··
Data are n (%) or median (IQR), unless otherwise stated.
Table 1: Patient characteristics
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Role of the funding source
Cancer Research UK’s clinical trials awards and advisory 
committee approved the trial design. Cancer Research 
UK had no role in study design, data collection, analysis 
or interpretation, or writing of the report. The statistician 
(CNH) had full access to all of the data, and he and the 
corresponding author (SM) had the ﬁ nal responsibility to 
submit for publication.
Results
Between Dec 24, 2009, and Oct 25, 2011, 114 patients were 
registered into the trial from 28 hospitals across the UK. 
All patients were followed until progression, death, or 
12-month follow-up assessment. 74 patients were eligible 
for randomisation after three cycles of induction 
chemotherapy; 38 were allocated to receive gemcitabine-
based chemoradiation and 36 to receive capecitabine-
based chemoradiation (ﬁ gure 1).
The baseline characteristics of age, disease location, 
and WHO performance status were well balanced 
between the groups, but the gemcitabine group had a 
higher proportion of men than did the capecitabine 
group (table 1). The median number of days from staging 
to registration and from registration to start of chemo-
therapy was low in both groups; additionally, the median 
time from registration to start of radiotherapy was the 
same in both groups (table 1). On-trial review of planning 
assessment forms showed a 100% compliance with the 
radiotherapy protocol. A separate detailed analysis of the 
radiotherapy quality assurance process and radiotherapy 
compliance is planned.
Table 2 shows treatment compliance during chemo-
radiotherapy. Two patients in the capecitabine group 
progressed before chemoradiation treatment could be 
started. Radiotherapy was well tolerated, with a slightly 
higher proportion of patients receiving at least 25 out of 
28 fractions in the capecitabine group than in the 
gemcitabine group. A slightly higher proportion of 
patients in the gemcitabine group had 4 weeks or more 
of concurrent chemotherapy prescribed at 100% of the 
protocol dose. However, fewer patients in the 
capecitabine group needed dose reductions or stopped 
chemotherapy early than did those in the gemcitabine 
group.
The main grade 3–4 toxic eﬀ ects that occurred during 
chemoradiotherapy are summarised in table 3. More 
patients in the gemcitabine group than in the capecitabine 
group had any grade 3 or 4 toxic eﬀ ects during induction 
chemotherapy (24 [67%] of 36 patients vs 17 [45%] of 38). 
During chemoradiotherapy, both regi mens were well 
tolerated, but a smaller proportion of patients in the 
capecitabine group had haematological and non-
haematological grade 3 or 4 toxic eﬀ ects (haematological: 
none vs seven [18%] of 38 patients; χ²=6·94, p=0·008; 
non-haematological: four [12%] of 34 patients vs ten [26%] 
of 38 patients; χ²=2·43, p=0·12). No treatment-related 
deaths occurred.
The primary endpoint of 9-month progression-free 
survival was assessable in 35 patients from each group (in 
the gemcitabine group, one patient was too ill for CT 
Induction 
chemotherapy 
(all randomised 
patients, n=74)
Chemoradiotherapy
Capecitabine 
group (n=34)*
Gemcitabine 
group (n=38)
Any grade 3–4 eﬀ ects 41 (55%) 4 (12%) 14 (37%)
Haematological 28 (38%) 0 7 (18%)
Haemoglobin 2 (3%) 0 0
Leucocytes 10 (14%) 0 5 (13%)
Absolute neutrophil count 28 (38%) 0 4 (11%)
Platelets 3 (4%) 0 1 (3%)
Lymphocytes 0 0 1 (3%)
Non-haematological 24 (32%) 4 (12%) 10 (26%)
Constitutional symptoms 2 (3%) 2 (6%) 5 (13%)
Fatigue 2 (3%) 2 (6%) 4 (11%)
Weight loss 0 0 1 (3%)
Dermatological symptoms 6 (8%) 0 0
Hand-foot syndrome 4 (5%) 0 0
Other 2 (3%) 0 0
Gastrointestinal symptoms 7 (9%) 0 6 (16%)
Diarrhoea 3 (4%) 0 3 (8%)
Nausea or vomiting 1 (1%) 0 3 (8%)
Anorexia 0 0 3 (8%)
Other 4 (5%) 0 0
Infection 8 (11%) 0 2 (5%)
Febrile neutropenia 2 (3%) 0 1 (3%)
Infection with normal neutrophil count 7 (9%) 0 1 (3%)
Vascular 3 (4%) 0 0
Thrombosis, thrombus, or embolism 2 (3%) 0 0
Other 1 (1%) 0 0
Metabolic (laboratory) 10 (14%) 1 (3%) 3 (8%)
Liver related 5 (7%) 0 1 (3%)
Other 7 (9%) 1 (3%) 2 (5%)
Other 4 (5%) 2 (6%) 3 (8%)
Data are n (%). *Two patients in the capecitabine group are excluded because they progressed during the fourth cycle 
of induction chemotherapy before any chemoradiation treatment could be given.
Table 3: Grade 3–4 toxic eﬀ ects
Capecitabine group 
(n=35*)
Gemcitabine group 
(n=36†) 
Complete response 2 (6%) 0
Partial response 6 (17%) 7 (19%)
Stable disease 22 (63%) 24 (67%)
Progressive disease 5 (14%) 5 (14%)
Response was determined according to RECIST (version 1.1) criteria. Data are n 
(%). *CT scan not done or invalid (ie, more than 4 weeks either side of 26 weeks) 
for one patient. †CT scan not done or invalid (ie, more than 4 weeks either side of 
26 weeks) for two patients.
Table 4: Objective disease response at 26 weeks from registration
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scan, one refused, and one died before the scan was due; 
in the capecitabine group, one patient had a CT scan done 
more than 4 weeks after the 9-month timepoint). 
22 patients (62·9%, 80% CI 50·6–73·9) in the capecitabine 
group had not progressed at 9 months, compared with 
18 patients (51·4%, 39·4–63·4) in the gemcitabine group.
Table 4 shows the objective disease response at 
26 weeks, 4 weeks after completion of chemo radiotherapy 
(when response conventionally reassessed). Five patients 
(two from the capecitabine group and three from the 
gemcitabine group) underwent resection of the primary 
tumour after completion of study treatment—four of 
these patients (two from each group) remained disease 
free at 52-week follow-up and one (from the gemcitabine 
group) died from postoperative complications (appen-
dix). Full histological assessments were done for all of 
the resected specimens and were reported as ypT1N0 
(n=1), ypT2N0 (n=1), and ypT3N0 (n=3); all had patho-
logically clear margins.
Median progression-free survival was 12·0 months 
(95% CI 10·2–14·6) in the capecitabine group and 
10·4 months (95% CI 8·9–12·5) in the gemcitabine 
group (unadjusted HR 0·64, 95% CI 0·37–1·09; log-
rank p=0·102; adjusted HR 0·60, 95% CI 0·32–1·12; 
p=0·11; ﬁ gure 2). Median local progression-free survival 
was 14·6 months (95% CI 11·3–18·6) in the capecitabine 
group and 12·0 months (9·8–14·0) in the gemcitabine 
group. Distant progres sion-free survival was 
14·3 months (95% CI 11·5–15·2) in the capecitabine 
group and 11·9 months (9·7–13·8) in the gemcitabine 
group. The pattern of disease progres sion at 12 months 
from registration is shown in table 5.
Median overall survival for all registered patients 
(n=114) was 12·7 months (95% CI 11·0–14·5); 12-month 
overall survival was 52·9% (95% CI 42·9–61·9). Patients 
who proceeded to be randomised to chemo radiotherapy 
(n=74) had a median overall survival of 14·6 months 
(95% CI 13·0–15·8) and 12-month survival of 77·5% 
(95% CI 65·8–85·6); patients who did not proceed to 
randomisation (n=40) had a median overall survival of 
8·1 months (95% CI 4·1–10·5) and 12-month survival of 
16·9% (95% CI 6·9–30·7). Median overall survival was 
15·2 months (95% CI 13·9–19·2) in the capecitabine 
group and 13·4 months (95% CI 11·0–15·7) in the 
gemcitabine group (unadjusted HR 0·50, 95% CI 
0·27–0·93; log-rank p=0·025; adjusted HR 0·39, 95% CI 
0·18–0·81; p=0·012; ﬁ gure 3). This diﬀ erence was 
maintained in a sensitivity analysis that included sex and 
CA19-9 concentration (imbalanced at randomisation) in 
the adjusted Cox regression (p=0·003). 12-month overall 
survival was 79·2% (95% CI 61·1–89·5) in the 
capecitabine group and 64·2% (95% CI 46·4–77·5) in the 
gemcitabine group.
We assessed quality of life with the QLQ-C30 
questionnaire (ﬁ gure 4, appendix). Despite an apparent 
diﬀ erence between the treatment groups, the scores at 
week 23 (immediately after completion of chemoradio-
therapy) were not signiﬁ cantly diﬀ erent (z=–1·492; 
p=0·14; n=48). Nor was the diﬀ erence between the 
changes in score from week 17 (before chemoradiation 
treatment) to week 23 signiﬁ cant (z=–1·514; p=0·13; 
n=45). A detailed quality-of-life analysis is planned.
No signiﬁ cant diﬀ erence in CA19-9 concentrations 
was detected between the capecitabine group and the 
gemcitabine group, either at baseline (table 1; z=1·500; 
p=0·13; n=67) or at week 17, immediately before chemo-
radiotherapy (capecitabine median 29 U/mL (17–170); 
gemcitabine median 130 U/mL (21–251); z=1·603; p=0·11; 
n=58), in randomised patients. We divided all patients 
into groups on the basis of whether or not their CA19-9 
concentrations at baseline and week 17 were lower than 
the median, and compared overall survival (table 6). 
Higher baseline CA19-9 was predictive of worse survival 
in both all recruited and all randomised patients (table 6). 
Higher week 17 CA19-9 concentrations were highly 
predictive of worse survival in randomised patients, but 
the fall in CA19-9 between baseline and week 17 was not. 
The signiﬁ cance of these results was maintained in 
multivariate models (table 6). The hazard ratio for overall 
Capecitabine 
group (n=36)
Gemcitabine 
group (n=38)
Alive with no progression 8 (22%) 7 (18%)
Died before progression 7 (19%) 9 (24%)
Disease progressed 21 (58%) 22 (58%)
Local 7 (33%)* 7 (32%)*
Metastatic 11 (52%)* 10 (45%)*
Both 3 (14%)* 5 (23%)*
Data are n (%). *Percentages are of number of patients whose cancer had 
progressed.
Table 5: Patterns of disease progression at 12 months from registration
Figure 2: Kaplan–Meier estimates of progression-free survival, by treatment group
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survival between the capecitabine and gemcitabine 
groups is more signiﬁ cant in patients with high CA19-9 at 
baseline (HR 0·30, 95% CI 0·11–0·79; p=0·014) than in 
those with low baseline CA19-9 (0·55, 0·17–1·82; p=0·33). 
CA19-9 measurements at week 17 and 26 (ie, after 
chemoradiotherapy) were available for only 43 (58%) of 
74 patients, which limits any further in-depth analysis.
Discussion
Our results show that induction chemotherapy followed 
by gemcitabine-based or capecitabine-based chemoradio-
therapy are both active regimens and can be given safely. 
The capecitabine-based regimen seems to have better 
safety and eﬃ  cacy outcomes than the gemcitabine-based 
regimen, although the diﬀ erence in progression-free 
survival at 9 months was not signiﬁ cant (panel).
Locally advanced pancreatic cancer has a poor prog-
nosis and treatment advances have evolved slowly. The 
contribution of radiotherapy to the improvement of 
survival and quality of life is a controversial issue, since 
many patients die from rapidly emerging metastatic 
disease. Survival of patients with locally advanced 
pancreatic cancer who are treated with chemotherapy 
alone, extracted from studies that combine patients with 
locally advanced pancreatic cancer and those with 
metastatic disease, ranges from 9·9 to 10·3 months.5,23 
Chemoradiotherapy for inoperable adenocarcinoma of 
the pancreas has been a standard treatment in the USA 
since a series of seminal studies from the Gastrointestinal 
Studies Group in 1981.6 The relative beneﬁ t attributed to 
chemoradiotherapy compared with radiotherapy alone 
could be due in part to the extended administration of 
maintenance chemotherapy after chemoradiation in 
combined modality trial groups, which suggests that 
additional systemic therapy might confer advantage. 
This strategy has not been widely used in the UK, partly 
because of logistical issues, but also because of a paucity 
of supportive evidence and the perceived toxicity of 
chemoradiotherapy in patients with such a poor outlook.
Trials in the past 6–7 years that have assessed 
chemoradiotherapy have started with induction 
chemotherapy, with chemoradio therapy given as a 
consolidation regimen for patients who do not develop 
metastases (typically 65–70% of patients). This approach 
enables the initiation of eﬀ ective, full-dose systemic 
therapy immediately after diagnosis, followed by 
intensiﬁ ed treatment at the primary site for optimum 
tumour control and, in some cases, downstaging to enable 
surgical resection. Non-randomised trials that have used 
this approach have reported survival outcomes of 
14–19 months in this select group of patients,9,13-17,20 and the 
results of one non-randomised study suggest that in 
patients with responding disease, this approach of 
switching to chemoradiotherapy could have better 
outcome than continuation of chemotherapy alone (overall 
survival of 15·0 vs 11·7 months, p=0·0009).9 A prospective, 
phase 3 trial (LAP-07) to assess the additional beneﬁ t of 
chemoradiotherapy in this setting has completed accrual 
in Europe. In this trial, after 3 months of induction 
chemotherapy, responding patients have been randomly 
allocated to either continue the same chemotherapy 
regimen or to switch to a capecitabine-based chemo-
radiotherapy regimen similar to that used for the 
capecitabine group in our study.
Our results suggest that the overall survival with 
induction chemotherapy followed by consolidation 
chemoradiotherapy seen here in a multicentre setting 
accords with the results of previous single-centre studies. 
40 registered patients did not receive chemoradiotherapy 
because of death (n=5), poor general condition (n=10), 
Figure 3: Kaplan–Meier estimates of overall survival, by treatment group
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Figure 4: Quality of life scores
Scores are from the QLQ-C30 questionnaire. Error bars show 95% CIs.
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progressive disease or ineligibility (n=16), or patient 
choice (n=9); in these patients median survival was only 
8·1 months (95% CI 4·1–10·1). However, the overall 
median survival of all registered patients was 12·7 months 
(95% 11·0–14·5), which is better than previous outcomes 
in chemotherapy-only studies (roughly 10 months).4,5
Grade 3–4 toxic eﬀ ects were less frequent during 
consolidation chemoradiotherapy than during induction 
chemotherapy. The selection of ﬁ tter patients through 
induction treatment, limited-ﬁ eld radiotherapy, con-
formal radiation techniques, and above all, the pro-
spective RTTQA programme will all have contributed to 
this favourable outcome. Moreover, because all patients 
received induction chemotherapy that used gemcitabine 
and capecitabine, potential chemotherapy-related toxic 
eﬀ ects were identiﬁ ed and appropriate measures taken, 
including dose reduction instituted before the start of 
chemoradiotherapy.
Of the previous studies that compared gemcitabine-
based and ﬂ uorouracil-based chemoradiotherapy,19–21 
at least one study19 and a meta-analysis22 suggested better 
survival outcomes with gemcitabine. However these 
studies used chemoradiotherapy without induction 
chemotherapy and were done in unselected patients. Our 
results showed a signiﬁ cant advantage for the secondary 
endpoint of overall survival in the capecitabine group 
compared with the gemcitabine group, and the diﬀ erence 
is clinically relevant, especially because of the apparently 
lower toxicity. Both distant and local progression-free 
survival seemed to be better in the capecitabine group as 
well, but the diﬀ erences in progression-free survival 
were not signiﬁ cant.
The rationale behind the previous studies that compared 
gemcitabine with ﬂ uorouracil in a chemo radiotherapy 
setting was based on the hypothesis that gemcitabine is a 
more potent radiosensitiser than ﬂ uorouracil; however, in 
the clinical setting diﬀ eren tiating between the 
radiosensitising eﬀ ect and the systemic contribution of 
the chemotherapy is diﬃ  cult. The size of beneﬁ t from 
capecitabine in our study was similar for both distant and 
local progression-free survival, which might suggest that 
the systemic eﬀ ect accounts for the diﬀ erence.
An optimum concurrent dose of gemcitabine in 
conjunction with radiotherapy has not been deﬁ ned. 
Gemcitabine is a potent radiosensitiser and increased 
doses of gemcitabine in combination with radiotherapy 
have been associated with heightened toxicity. In phase 
1–2 clinical trials, once-per-week doses of gemcitabine 
have ranged from 250 mg/m² to 1000 mg/m², and the 
only phase 3 trial7 to use gemcitabine as a radiosensitiser 
used a dose of 600 mg/m². That trial,7 in which patients 
were randomly assigned to receive either gemcitabine 
alone or gemcitabine with radiotherapy (50·4 Gy in 
28 fractions), was stopped early because of poor 
recruitment, with 71 patients entered from eight US 
centres. Survival was slightly better in the 
chemoradiotherapy group than in the chemotherapy-
only group (11·1 vs 9·2 months, p=0·017), but at the 
expense of increased grade 4–5 toxic eﬀ ects (41% vs 9%). 
Phase 1–2 studies that used full-dose gemcitabine in 
combination with radical doses of radiotherapy have also 
been reported.27,28 Although outcomes from these studies 
are promising and the toxicities are acceptable, the trials 
were done in a small number of experienced centres, and 
the results might not be reproducible in a large 
multicentre setting.
In our study we used a fairly low dose of gemcitabine 
(300 mg/m² once per week). This reduced dose could 
possibly account for the diﬀ erence in survival outcomes 
between the gemcitabine and capecitabine groups, since 
the reduction in dose of systemic therapy in the 
gemcitabine group might have compromised the 
outcome, whereas adequate systemic therapy was 
maintained in the capecitabine group. We can speculate 
that increasing the dose of gemcitabine chemoradio-
therapy might have improved the survival outcomes in 
this group, but doing so would also have increased the 
frequency of grade 3–4 toxic eﬀ ects.
The suggestion that the diﬀ erence in outcomes between 
the treatment groups in our study could have been caused 
by a reduction in systemic therapy in the gemcitabine 
group would be consistent with evidence that systemic 
therapy is important in the management of locally 
advanced pancreatic cancer, as was shown by Chauﬀ ert 
and colleagues,7 in whose study compromise in the 
systemic adjuvant chemotherapy after primary ﬂ uorouracil 
and cisplatin-based chemoradiotherapy resulted in a poor 
outcome compared with chemo therapy alone. Additionally, 
n Median CA19-9 (IQR), 
U/mL
Overall survival in months (95% CI) Univariate Multivariate*
CA19-9 less than median CA19-9 median or higher Hazard ratio (95% CI) p value Hazard ratio (95% CI) p value
Baseline in all patients 106 331·5 (75–1074) 15·7 (12·9–16·5) (n=53) 10·4 (9·3–11·7) (n=53) 2·49 (1·53–4·03) <0·001 2·53 (1·53–4·20) <0·001
Baseline in randomised patients 67 212 (71–829) 16·3 (15·2–20·7) (n=33) 11·3 (9·7–13·4) (n=34) 4·29 (2·14–8·59) <0·001 4·19 (2·09–8·40) <0·001
Week 17 in randomised patients 58 44 (19–208) 16·3 (13·9–19·2) (n=29) 12·6 (10·3–14·0) (n=29) 3·37 (1·67–6·81) 0·001 3·84 (1·67–8·80) 0·002
Percentage fall in CA19-9 
between baseline and week 17
54 –74·8% (–89·0 to –53·2) 14·6 (10·3–19·2) (n=27) 14·0 (12·7–16·0) (n=27) 1·26 (0·63–2·56) 0·51 1·12 (0·51–2·44) 0·780
*For all patients variables include sex, age, and WHO performance status; for randomised patients disease location is also included (centre could not be used because of small numbers).
Table 6: Overall survival by CA19-9 concentration at baseline and week 17
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in a retrospective series29 of 85 patients that compared 
outcomes in patients who received adjuvant chemotherapy 
after primary gemcitabine-based chemoradiotherapy with 
those who did not, 2-year overall survival was signiﬁ cantly 
better in those who received the adjuvant treatment (31·8% 
vs 12·4%, p<0·001). Neither our study nor LAP-07 recom-
mended continuation of chemotherapy after chemo-
radiotherapy, because chemotherapy was given upfront in 
both. Whether recommencement of chemotherapy after 
chemoradiotherapy would provide additional bene ﬁ t 
remains unknown. Nevertheless, in our trial, durable 
disease control was achieved with a median progression-
free survival of 12 months in the capecitabine-based 
chemoradiation group. This ﬁ nding suggests that in 
appropriately selected patients chemoradiotherapy can 
eﬀ ectively delay tumour progression, even if chemo-
therapy is not recommenced. The roles of newer 
chemotherapy regimens such as FOLFIRINOX or of the 
continuation of further systemic treatment after chemo-
radiotherapy remain to be tested in future randomised 
studies.
Our study had several limitations. Although our 
results show a clinically relevant diﬀ erence in overall 
survival between capecitabine-based and gemcitabine-
based chemoradiotherapy, this ﬁ nding should be 
interpreted cautiously since this outcome was not the 
primary endpoint and the number of patients included 
in the trial was small. Data for second-line treatment 
after disease progression were not obtained and an 
imbalance between the groups in terms of the 
proportion of patients who received second-line 
treatment might have aﬀ ected the survival outcomes. 
Moreover, although randomised, the Fleming’s design 
is not ideal for a direct comparison between the groups, 
and the trial would not have been adequately powered to 
detect a diﬀ erence in overall survival as the primary 
endpoint. We also acknowledge the limitations of 
progression-free survival as an endpoint for pancreatic 
cancer—since the primary tumour has diﬀ use margins, 
accurate measurement of local progression is diﬃ  cult. 
However, nearly 70% of the patients had new-onset 
metastatic disease at progression.
The trial protocol did not specify the criteria for 
inoperability, with this decision left to the locoregional 
pancreatic team (including the surgeon and specialist 
radiologist), in recognition of the variability in surgical 
practice. Most surgeons in the UK follow National 
Comprehensive Cancer Network guidance and we expect 
that this guidance was applied, although no central review 
of radiology took place. However, the protocol did specify 
that all patients had to be discussed at the multidisciplinary 
team meeting after chemoradiotherapy and be reassessed 
for operability. That few patients ultimately underwent 
operations suggests that the patients recruited to this trial 
had truly inoperable disease.
Despite its limitations, ours is the largest trial so far 
to report the outcome of consolidation chemoradio therapy 
after a course of induction chemotherapy. The combination 
of radiotherapy with capecitabine was less toxic than the 
combination with gemcitabine, despite gemcitabine being 
given at a fairly low dose. This beneﬁ t was achieved with 
no compromise in progression-free survival and local 
control, and an apparent improvement in overall survival. 
Notwith standing the small number of patients in this trial, 
the good eﬃ  cacy and toxicity proﬁ le seems to favour 
capecitabine for combination with radiotherapy in this 
setting, which suggests that capecitabine could be favoured 
as a template regimen in trials to assess new 
radiosensitisers or radiotherapy dose escalation.
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Panel: Research in context
Systemic review
We searched PubMed for research articles published in English 
before January 15, 2013, using the keywords “locally advanced 
pancreatic cancer” and “chemoradiotherapy”, and identiﬁ ed 
179 articles. No randomised controlled trials or retrospective 
studies compared gemcitabine-based with capecitabine-
based chemoradiotherapy. We identiﬁ ed two randomised 
trials19,21 that compared gemcitabine-based with 
ﬂ uorouracil-based chemoradiotherapy and one25 that 
compared gemcitabine-based with paclitaxel-based 
chemoradiotherapy. We also identiﬁ ed one meta-analysis22 
that compared gemcitabine-based with ﬂ uorouracil-based 
chemoradiotherapy. This meta-analysis included one 
additional randomised trial26 that was not identiﬁ ed in the 
original PubMed search, and therefore included three 
randomised trials and one retrospective comparative study,20 
with a total of 229 patients. The results showed an overall 
survival advantage for gemcitabine compared with 
ﬂ uorouracil at 12 months from randomisation (risk ratio 1·54, 
95% CI 1·05–2·26, p=0·03). Severe haematological toxic 
eﬀ ects were more frequent in the gemcitabine group.
Interpretation
The higher toxicity of gemcitabine compared with the 
ﬂ uorouracil prodrug capecitabine seen in our study is 
consistent with previous research. However, by contrast with 
previous evidence, our results seem to show a survival 
advantage from capecitabine-based compared with 
gemcitabine-based chemoradiotherapy. Although these data 
should be interpreted with caution, because the diﬀ erence in 
the primary endpoint was non-signiﬁ cant and the number of 
patients small, in the setting of induction chemotherapy, 
capecitabine-based chemoradiotherapy is safe and eﬀ ective 
and might be preferable to gemcitabine-based 
chemoradiotherapy for patients with locally advanced 
pancreatic cancer.
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